DarioHealth (Nasdaq:DRIO) announced today that it closed a senior secured term loan facility worth up to $50 million.
OrbiMed, a leading healthcare investor, will provide non-dilutive capital to fund the continued development of New York-based DarioHealth’s digital health platform for managing chronic diseases, including diabetes.
Get the full story at our sister site, Drug Delivery Business News.
The healthcare investment firm OrbiMed (New York City) has added two members to its team, including Dr. Tal Zaks, the former chief medical officer (CMO) at Moderna. Zaks will be a venture partner at Orbimed. Also joining the firm is Dr. Sheila Gujrathi, who was formerly the CEO of Gossamer Bio, who will be a venture advisor at OrbiMed.
Dr. Tal Zaks
Zaks spent six years at Moderna, where he was involved in the company’s metamorphosis from private biotech to COVID-19 vaccine pioneer with a sizable research pipeline in multiple therapeutic areas.
As for Gujrathi, she has experience in various companies, including Receptos, which Celgene acquired in 2015. She has also worked as a physician and management consultant at McKinsey and held several other leadership positions. Gujrathi also serves as the director of the board at Janux Therapeutics, chair of the board of directors at ADARx Pharmaceutics an…